Robert Leasure, Jr.
Chief Executive Officer, President and Director
Robert Leasure, Jr., has been the CEO, President and a Director of Bioanalytical Systems, Inc., since January 12, 2019. Prior to being promoted to CEO, Mr. Leasure started working with BASi’s management team in September 2016 as a consultant with LS Associates. In this role, he worked closely with the Company’s management team and board of directors to guide operations and assist BASi in restructuring, developing a growth strategy for the Company, initiating major expansion, and completing an acquisitions. Robert Leasure, Jr., serves as the managing partner and president of LS Associates LLC (“LS”), a management consulting firm formed in 2002. Over the last sixteen years, LS has worked with over 300 companies and served clients in the United States and internationally in various industries. Mr. Leasure brings over thirty years of experience in turnarounds, restructurings, financings, mergers and acquisitions, and building & mentoring management teams.
John Sagartz, DVM, PhD, DACVP
Chief Strategy Officer and Director
Dr. Sagartz has been the Chief Strategy Officer at Bioanalytical Systems, Inc., since November 1, 2018, and has been its Director since July 2, 2018. As Chief Strategy Officer, Dr. Sagartz helps define and accelerate the plans for growth of the Company. Dr. Sagartz founded and led Seventh Wave Laboratories for over fifteen years prior to BASi’s acquisition of its operations in July of 2018. Following the acquisition, Dr. Sagartz joined BASi’s Board of Directors to help guide operations to provide broader solutions and greater scientific expertise to the Company’s clients. Dr. Sagartz began his career as a toxicologic pathologist at Searle/Monsanto in 1996, and held positions of increasing responsibility as section head, director, preclinical development site head, and fellow, following Monsanto’s merger with Pharmacia. After Pfizer’s acquisition of Pharmacia in 2003, Dr. Sagartz founded Seventh Wave Laboratories where he served as President and Chief Executive Officer, and Chief Strategy Officer. He received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Kansas State University and, after completing residency training in anatomic pathology, earned his Doctor of Philosophy from The Ohio State University.
Scott Daniels, PhD
Senior Vice President, DMPK
Dr. Daniels joined BASi in March 2019 as the Senior Vice President of Drug Metabolism and Pharmacokinetics (DMPK). Dr. Daniels is an accomplished executive in pharmaceutical research and development, and brings over fifteen years of experience and leadership to the Company. He has advanced the fields of biotransformation and drug metabolism during tenures at DuPont Pharmaceuticals, Millennium, Pfizer, and Precera Biosciences, publishing in areas of drug metabolism, chemical toxicology and pharmacology. Prior to joining BASi, Dr. Daniels was Chief Scientific Officer at Precera Biosciences, and Director of Drug Metabolism and Pharmacokinetics (DMPK) in the Center for Neuroscience Drug Discovery at Vanderbilt University Medical School. Dr. Daniels is an Adjunct Professor of Pharmacology at Vanderbilt University School of Medicine, and an Advisory Committee Member of the Cleveland Clinic Center for Therapeutics Discovery. Dr. Daniels received his undergraduate degree in Biology and Chemistry from Southwest Baptist University and his doctorate in Chemistry at University of Missouri-Columbia, and performed his post-doctoral research in chemical toxicology at Vanderbilt University Medical Center.
Mike Dorato, PhD, DABT, Fellow ATS
Senior Vice President, Toxicology and Pharmacology
Dr. Dorato has over 40 years of experience as a researcher and global leader of safety and efficacy in the pharmaceutical and CRO industries. Prior to joining BASi in May 2019 as part of the Smithers Avanza Toxicology Services acquisition, he was Executive Vice President of Toxicology Services (Smithers Avanza Toxicology Services, 5 years), Vice President and CSO Global Discovery Services (Covance, 5 years) and Executive Director Toxicology and Greenfield Laboratories Site Head (Eli Lilly and Co., 30 years). In these positions, he led global organizations in safety and efficacy lead optimization, investigative and regulatory toxicology, discovery and late phase pathology, animal welfare, molecular and anatomical imaging, in vivo pharmacology, developmental and reproductive toxicology, veterinary medicine and model development. Dr. Dorato is a member of SOT and ACT and is active as a mentor for new professionals. He has had adjunct professorships at St. John’s University and Butler University, and is a Visiting Scholar at St. John’s University.
Stewart B. Jacobson, DVM, DACVP
Vice President, Pathology
Dr. Jacobson joined BASi on October 1, 2019, as Vice President of Pathology. Dr. Jacobson is an accomplished executive, skilled in strategic leadership, and brings over eighteen years of experience to the Company. He has held roles of increasing responsibility, leading teams and supporting nonclinical research in multiple well-known contract research organizations. His appointment allows the Company to accelerate the growth of its pathology center of excellence, and represents an important milestone in the Company’s succession planning.
Before joining BASi, Dr. Jacobson led the operations of the anatomic and clinical pathology sections at Battelle Memorial Institute. Prior to Battelle, Dr. Jacobson held senior leadership positions at SNBL USA, CVPath Institute, and Pathology Associates within Charles River Laboratories. Dr. Jacobson began his pathology career at Covance Laboratories as a Staff Pathologist.
Dr. Jacobson received a Bachelor of Science degree in Engineering/Computer Science from the University of Illinois. He went on to study veterinary medicine at Tufts, where he received his Doctor of Veterinary Medicine, then completed a Residency in Veterinary Anatomic Pathology from the University of Connecticut.
Chief Operating Officer
Mr. D. Thomas Oakley was appointed COO at BASi on February 11, 2019, and is responsible for leading its operations among four sites. Mr. Oakley joined BASi as part of the Seventh Wave acquisition in 2018, where Oakley previously served as CEO. Prior to his tenure at Seventh Wave Laboratories, Mr. Oakley led DTO Associates and served as President and COO of MPI Research, President and CEO of ChanTest Corporation, and President and CEO of Bridge Laboratories. He has also held leadership positions with the Sarah Cannon Research Institute and Covance. He served in the United States Army, from which he was honorably discharged with the rank of Captain. Mr. Oakley holds an MBA in management, finance and accounting from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BA in Economics from Ripon College.
Senior Vice President, Preclinical Services
Philip has over 22 years of pharmaceutical experience in drug discovery, toxicology/non-clinical, and clinical research. Traditionally trained as a bioanalytical chemist, Philip joined BASi as an analytical chemist in 1997, rapidly moving into leadership positions such as Director of Analytical Services, General Manager, and Sr. Director of Preclinical, until reaching his present position as Vice President of Preclinical Services. Prior to BASi, Philip worked at GFi Pharmaceuticals (now Covance Labs – Clinical Division) as an Analytical Scientist, and RSO designing and validating radiolabeled and non-radiolabeled assays used to support clinical ADME studies. He earned a Bachelor’s Degree in Chemistry and Biology from Indiana University and is a member of the Society of Toxicology, American College of Toxicology and the American Chemical Society.
Mike Baim, PhD
Senior Vice President, Analytical Operations
Dr. Michael Baim joined BASI in May 2018 as Senior VP of Analytical Operations. Dr. Baim is an energetic and passionate leader who brings to BASi over thirty years of experience in the pharmaceutical and lab management industries. He is well-versed in analytical methodology and project design, and has a proven track record of delivering significant and sustainable profitable growth across many different business segments. Dr. Baim began his career at The Procter & Gamble Company in 1984, and has since held several leadership, management and technical positions at other prominent companies including Novartis and Bristol-Myers Squibb/Mead Johnson. Most recently, he served as an analytical laboratory director, designing a new analytical chemistry lab and revitalizing chemistry operations by adding new technologies and staff to optimize technical guidance and improve customer service. These efforts resulted in a sustained, double-digit growth rate for the company. Dr. Baim received his BA in chemistry from Whitman College in Washington State. He then studied analytical chemistry as an American Chemical Society Analytical Research Fellow at Washington State University, where he earned his PhD. He is currently working towards his MBA in marketing management.
Beth A. Taylor, CPA
Vice President of Finance and Chief Financial Officer
Beth Taylor joined Inotiv in March 2020, with an extensive background in corporate and operational finance and accounting. She possesses exceptional experience and expertise in business planning, technical accounting, compliance, and investor relations for public companies, and a successful track record of cultivating support and relationships within organizations to achieve goals.
Prior to joining Inotiv, Beth held progressively responsible VP of Finance, Controllership and other financial leadership positions at Endocyte, Inc., Author Solutions, Inc., Harlan Laboratories, Inc., Republic Airways Holdings and Rolls-Royce Corporation. She started her career in audit with Deloitte and received her B.S. in Accounting from Indiana University’s Kelly School of Business in Bloomington, Indiana.
Chief Commercial Officer
Joe Flynn joined BASi in July 2018 as part of the Seventh Wave acquisition. He was appointed to his current role as the Chief Commercial Officer in February 2019. In this role, Joe is responsible for leading sales and marketing efforts across BASi’s four sites. Mr. Flynn has an esteemed career as a senior executive in contract research, with over 25 years of strategic and operational experience focusing on pharmaceutical research and development. Most recently, he served as Chief Commercial Officer and Executive Vice President of Seventh Wave Laboratories. Prior to his tenure at Seventh Wave Laboratories, Mr. Flynn was a global vice president of sales and client services for multiple divisions of Covance Laboratories. Prior to Covance, he held operational roles at PPD Inc. and ABC Laboratories (now Eurofins). Mr. Flynn began his career with a BS in Biochemistry from the University of Missouri, Columbia.
Chief Human Resources Officer
William Pitchford brings over 35 years of human resources experience to BASi’s leadership team, with respect to benefit and compensation design, executive coaching, acquisitions and divestitures, and interacting with public boards. As Chief Human Resources Officer, he leads all aspects of human resources, including performance and talent management, leadership development, compensatory rewards, and employee engagement, to ensure BASi’s culture and people strategies align with its overall business strategy. Prior to joining BASi, Mr. Pitchford held senior level positions within the human resources functions at Ford Motor Company, Rio Tinto Alcan Corporation and, most recently, at Wabash National Corporation as Senior Vice President of Human Resources. Mr. Pitchford received his undergraduate degree in Criminology & Sociology at Indiana State University, and his Master of Arts in Human Resources Management at Central Michigan University.